Condition: Primary Sclerosing Cholangitis · Liver and Intrahepatic Bile Duct Disorder · IBD · Sponsor: University of Milano Bicocca
Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver. There is still no medical therapy proven to halt the progression of PSC or prevent its serious complications. This is a Phase 2 randomized, double bind, placebo-controlled, monocentric study evaluating the safety and efficacy of two doses of oral vancomycin (i.e. 750 mg and 1500 mg/day) in subject between 15 - 70 years old with PSC.
This description comes directly from the study's public registry record.
Marco Carbone, MD · 0392334515 · marco.carbone@unimib.it
Pietro Invernizzi, MD · 039 233 2187 · pietro.invernizzi@unimib.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS San Gerardo dei Tintori | Monza, Monza E Brianza, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05876182